Budget impact analysis for the Health Care Package by using MammaPrint in Belgium
ย Publication: ESMO BREAST CANCER CONGRESS 2022 Authors De Lameillieure Read More
Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests
Publication: ESMO BREAST CANCER CONGRESS 2022 Authors Esther Schuler(1), Read More
MINDACT: Outcomes of any adjuvant systemic treatment in ESBC
Annals of Oncology, Volume 33, Issue 3, March 2022, Pages 310-320 Authors: Lopes Cardozo et al.
Read MoreMINDACT Trial: Outcome of Patients with UltraLow Risk, JCO 2022
Journal of Clinical Oncology, Volume 40, Number 12, January 21, 2022 Authors: Audeh et al.
Read MoreDurvalumab + olaparib + paclitaxel in High-risk HER2-negative ESBC: I-SPY2 trial results
I-SPY2 Trial, Cancer Cell 39, 989โ998, 2021 Authors: Pusztai et al.
Read MoreMolecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 ย Authors Joyce OโShaughnessy1, Virginia G. Read More
Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients โค 50 years and > 50 years
PUBLICATION: ASCO 2021 ย Authors Cathy Graham1, Douglas K. Read More
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina DโAbreo1,2, Abhinav Rohatgi1,2, Douglas Read More
B-42 Trial: MammaPrint Utility for Prediction of Extended Letrozole Therapy, ASCO 2021
NSABP B-42 Trial, ASCO 2021 Abstract #502 Authors: Rastogi, et al.
Read MoreMammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
ย Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
